β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Open accessThe DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 55 of the 76 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. CONCLUSIONS: β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to (1) impact the natural history of β-cell failure; (2) identify and characterize genetic loci for T2D; (3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; (4) develop alternative sources of β-cells for cell-based therapy; (5) focus on metabolic environment to provide indirect benefit to β-cells; (6) improve understanding of the physiology of responses to bypass surgery; and (7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.
Overview
CoChat Summary
TL;DR
This review/consensus report from an international expert meeting argues that progressive β-cell failure is central to type 2 diabetes, involving genetic/epigenetic changes and multiple stressors that lead to dysfunction, dedifferentiation, and death. It concludes existing therapies can improve β-cell function temporarily but generally do not arrest or reverse progression, with possible exception of gastric bypass, and identifies noninvasive β-cell mass measurement and stage-specific/combinatorial interventions as key research needs.
Key findings
- Over 60 genetic loci have been convincingly associated with T2D, the great majority involved in some way in β-cell biology, but these variants explain only a small proportion of total genetic risk; approximately 50% of T2D-associated SNPs introduce or remove a CpG site, suggesting genetic-epigenetic interactions.
- β-cell mass in T2D varies and overlaps with normal individuals, although current data suggest a 20–60% reduction; human β-cell mass varies three- to fivefold unrelated to age or BMI, and insulin sensitivity may vary as much as 10-fold. β-cell function and mass declines are not well correlated, while deteriorating β-cell function is tightly correlated with climbing glucose levels.
- Multiple stressors are implicated: ER stress, metabolic/oxidative stress, amyloid/IAPP oligomers, islet inflammation (IL-1β antagonism can preserve some β-cell functional mass), and disrupted islet integrity. β-cell dedifferentiation has regained favor, and residual β-cells remain even in late disease.
- Interventions show temporary β-cell functional improvement: in the DPP, greater baseline β-cell function and insulin sensitivity independently contributed to restoration of normal glucose tolerance; TZDs improved the oral disposition index; GLP-1–based therapies improve function during treatment but no meaningful persistent change follows withdrawal; RYGB produces disease remission in at least 80% of patients, with duration of diabetes and insulin use before surgery as strongest predictors.
Methods
- Design: narrative review/consensus report from the October 2013 meeting “Beta Cell Failure in Type 2 Diabetes,” cosponsored by the Endocrine Society and the American Diabetes Association, assembling international experts to review the state of the science and identify research needs.
- Data/sample: no primary experimental sample; synthesis of published human and animal studies, including genetics, epigenetics, islet biology, clinical trials, and surgical interventions.
- Analysis: expert discussion and narrative synthesis; future research goals are presented in Table 1 (not included in the provided text).
Limitations
- Stated: studies of epigenetics in T2D are severely limited by the small number of islets available from patients with T2D and by difficulty separating cause and effect in hyperglycemia; human β-cell mass measurement relies entirely on postmortem, cross-sectional assessments, and histomorphometric measurement of β-cell area, volume, and mass is often imprecisely defined and complicated by technical inconsistencies.
- Stated: no study has established whether one pathogenic pathway dominates or can serve as a single major target; durability of β-cell functional improvements following therapy withdrawal remains challenging, and whether earlier intervention can alter the natural history of β-cell failure is unknown.
- Evident from the text: as an expert consensus/narrative review, it does not describe a systematic search strategy or quantitative meta-analysis, and many cited mechanisms and genetic associations remain uncertain or require human validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
35 Valid · 6 Not valid · 7 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“At the time of writing, over 60 genetic loci have been convincingly associated with T2D”
What the sources say
- Disputedcites [8] Voight, 2010, Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis, Nat Genet sourceExperimental — accuracy not yet measured
The Discussion states that the number of confirmed T2D loci stood at 38 when the source paper was written, not over 60. The paper cannot establish a later count at the citing document’s time of writing. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [9] Rosengren, 2012, Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes, Diabetes sourceExperimental — accuracy not yet measured
The source paper's Abstract says recent genome-wide association studies had identified close to 50 loci associated with T2D risk, not over 60. Its count is contrary to the number attributed to it. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
What the sources say
- Not checked — no full text of the sourcecites [71] Fehse, 2005, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes, J Clin Endocrinol Metab source
- Disputedcites [73] Bunck, 2011, Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
The Results (Measures of β-cell function; page unavailable) report a sustained improvement in the disposition index four weeks after exenatide withdrawal, contrary to the categorical claim that none of these agents produced a persistent change. The Conclusions call the effect small and note that it was not enough to sustain glycemic control; the Results (Glycemic control; page unavailable) report that HbA1c and fasting glucose returned to pretreatment values after 12 weeks off treatment. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“further suggest that hyperglycemia alters DNA methylation of PDX1 and INS ( 22 – 25 ).”
What the sources say
- Partly supportedcites [22] Yang, 2012, Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes, Mol Endocrinol sourceExperimental — accuracy not yet measured
The 'Impact of hyperglycemia on DNA methylation of PDX-1' section (page not supplied) reports that HbA1c correlated with PDX-1 methylation in human islets and that high glucose nominally increased Pdx-1 methylation in rat β-cells. The paper does not present a corresponding finding that hyperglycemia alters INS methylation; its Discussion mentions insulin-promoter methylation in patients with type 2 diabetes as a finding from earlier work. (LLM, conf=0.85)
- Supportedcites [23] Yang, 2011, Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets, Diabetologia source
The Discussion reports that 72 hours of hyperglycaemia increased insulin-promoter DNA methylation in clonal rat beta cells, supporting the INS part for which this paper is cited. PDX1 appears only as an insulin-promoter binding-site label in the Results figure caption; this paper is not the source for that part of the multi-citation sentence. (LLM, conf=0.90)
- Could not verifycites [24] Ling, 2008, Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion, Diabetologia sourceExperimental — accuracy not yet measured
The Methods and Results (page not available) examine DNA methylation of PPARGC1A and report higher methylation in diabetic than non-diabetic islets. Searches for PDX1, INS, and hyperglycemia-related methylation found no passage addressing whether hyperglycemia alters methylation of PDX1 or INS. (LLM, conf=0.74)
- Disputedcites [25] Volkmar, 2012, DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients, EMBO J sourceExperimental — accuracy not yet measured
The Results section, “Differential DNA methylation observed in T2D islets is not inducible by high glucose” (page unavailable), reports no significant methylation changes at the tested sites after high-glucose exposure and concludes that T2D-related methylation differences are probably not secondary to hyperglycaemia. It does not report a high-glucose effect on PDX1 or INS specifically, so its findings do not establish the opposite for those two genes; nevertheless, the paper’s stated conclusion runs contrary to the claim attributed to it. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“knockout of miR-375 promotes progressive hyperglycemia in mouse models due to decreased insulin content and progressive loss of β-cell mass ( 32 ).”
What the sources say
- Disputedcites [32] Poy, 2009, miR-375 maintains normal pancreatic alpha- and beta-cell mass, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The Results report hyperglycemia and reduced β-cell mass in miR-375 knockout mice, but the measured mass deficit was 38% at 3 weeks and 31% at 10 weeks, not a progressive loss. The Discussion explicitly attributes their hyperglycemia primarily to an α-cell defect and says the reduction in β-cell mass is unlikely to explain it; plasma insulin was unchanged in these mice. Insulin-deficient diabetes was reported for the separate obese 375/ob model. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Powerful evidence for a genetic component to T2D ( 1 ) has driven extensive efforts to identify genetic variants contributing to risk.”
What the sources say
- Supportedcites [1] Meigs, 2000, Parental transmission of type 2 diabetes: the Framingham Offspring Study, Diabetes source
The paper's Abstract calls type 2 diabetes heritable and says twin concordance, population patterns, and family aggregation support genetic determinants. Its Discussion also considers paternal genetic factors in diabetes risk. (LLM, conf=0.93)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims · 21 with their cited sources checked
Create a free account to see all 74 claims and every source verdict.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [38]
Experimental — accuracy not yet measured
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336 · cited 1×
“case, these variants explain only a small proportion of total genetic risk (11).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737 · cited 1×
“esis (46), results from a janitorial macrophage infiltration to clear damaged islet b-cells and/or an innate”
BackgroundA pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Self-citationMasters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“levels that allow proapoptotic IAPP oligomers to form (44) that induce interleukin (IL)-1b release to recruit macrophages and enhance local islet inflammation (45).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“GLP-1based therapies magnify glucose-stimulated insulin secretion, as seen with significantly improved β-cell function in T2D following short-term infusions of GLP-1 (68, 69) and longer-”
Influential
Cited by
Items 101–200 of 462
Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Nakanishi, S., Mune, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157917 · Cited by 51
Gao, D., Jiao, J., Wang, Z., Huang, X., Ni, X., Fang, S., Zhou, Q., Zhu, X., Sun, L., Yang, Z. R., et al. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.04.002 · Cited by 53
Optical tools for understanding the complexity of β-cell signalling and insulin release
Frank, J. A., Broichhagen, J., Yushchenko, D. A., Trauner, D. H., Schultz, C., & Hodson, D. J. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0105-2 · Cited by 48
Micro(RNA) Management and Mismanagement of the Islet
Eliasson, L., & Regazzi, R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.09.017 · Cited by 52
Vals‐Delgado, C., Alcala-Diaz, J. F., Molina‐Abril, H., Roncero‐Ramos, I., Caspers, M. P. M., Schuren, F. H. J., van den Broek, T. J., Luque, R. M., Pérez‐Martínez, P., Katsiki, N., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.05.001 · Cited by 53
“Insulin resistance (IR) along with impaired beta-cell function are critical determinants of this disease [1].”
BackgroundGuo, P., Zhou, Q., Ren, L., Chen, Y., & Yue, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.005 · Cited by 53
Chen, L., Zhang, J., Li, C., Wang, Z., Li, J., Zhao, D., Wang, S., Zhang, H., Huang, Y., & Guo, X. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.05.007 · Cited by 48
Combinatorial transcription factor profiles predict mature and functional human islet α and β cells
Shrestha, S., Saunders, D. C., Walker, J. T., Camuñas-Soler, J., Dai, X.-Q., Haliyur, R., Aramandla, R., Poffenberger, G., Prasad, N., Bottino, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151621 · Cited by 52
Self-citationBoland, B. B., Brown, C., Boland, M. L., Cann, J., Sulikowski, M., Hansen, G., Grønlund, R. V., King, W., Rondinone, C., Trevaskis, J., et al. (2019) · Diabetes · doi:10.2337/db18-0304 · Cited by 47
Self-citationWu, S., Gao, L., Cipriani, A., Huang, Y., Yang, Z., Yang, J., Yu, S., Zhang, Y., Chai, S., Zhang, Z., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13613 · Cited by 48
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe, G., Ciccarelli, G., Soldovieri, L., Capece, U., Cefalo, C. M. A., Moffa, S., Nista, E. C., Brunetti, M., Cinti, F., Gasbarrini, A., et al. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.02.001 · Cited by 46
“These events alter the physiological mobilization of Ca from the ER, favoring proapoptotic signals and the degradation of proinsulin mRNAs, thus inducing the release of interleukin (IL)-1β, which recalls macrophages and increases insular inflammation [49].”
Blevins, T., Pieber, T. R., Colón Vega, G., Zhang, S., Bastyr, E. J., Chang, A. M., & on behalf of the IMAGINE 4 Investigators (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12696 · Cited by 45
Lyu, X., Zhu, X., Zhao, B., Du, L., Chen, D., Wang, C., Liu, G., & Ran, X. (2017) · Scientific Reports · doi:10.1038/srep44865 · Cited by 50
Dysfunction and Therapeutic Potential of Endothelial Progenitor Cells in Diabetes Mellitus
Li-dong, H., Dai, S.-C., Luan, X., Chen, J., & Cannavicci, A. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3581w · Cited by 47
Terauchi, Y., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12957 · Cited by 48
Glycogen phosphorylase inhibition improves beta cell function
Nagy, L., Márton, J., Vida, A., Kis, G. N., Bokor, É., Kun, S., Gönczi, M., Docsa, T., Tóth, A., Antal, M., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13819 · Cited by 48
“…major regulator of beta cell function, persistent hyperglycaemia combined with peripheral insulin resistance in type 2 diabetic conditions results in the beta cells being overworked to maintainnormal blood glucose levels (Abdul-Ghani, 2013; Cerf, 2013; Halban et al., 2014; MacDonald et al., 2005).”
BackgroundCyb5r3 links FoxO1-dependent mitochondrial dysfunction with β-cell failure
Fan, J., Du, W. J., Kim-Muller, J. Y., Son, J., Kuo, T., Larrea, D., Garcia, C., Kitamoto, T., Kraakman, M. J., Owusu-Ansah, E., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.008 · Cited by 44
“A hallmark of diabetes is b-cell failure, a state of chronically increased demand for insulin that exceeds the b-cell’s secretory capacity and leads to a gradual deterioration of b-cell mass and function [1,2].”
BackgroundElsayed, R. H., Kamel, E. M., Mahmoud, A. M., El‐Bassuony, A. A., Bin-Jumah, M. N., Lamsabhi, A. M., & Ahmed, S. A. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111202 · Cited by 49
Targeting BRD9 for Cancer Treatment: A New Strategy
Zhu, X., Liao, Y., & Tang, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s286867 · Cited by 47
The Role of Beta Cell Recovery in Type 2 Diabetes Remission
Suleiman, M., Marselli, L., Cnop, M., Eizirik, D. L., Luca, C. D., Femia, F. R., Tesi, M., Guerra, S. D., & Marchetti, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137435 · Cited by 49
The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia
Jagannathan, R., Buysschaert, M., Medina, J. L., Katz, K., Musleh, S., Dorcely, B., & Bergman, M. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1105-3 · Cited by 43
Germoush, M. O., Elgebaly, H. A., Hassan, S. M., Kamel, E. M., Bin-Jumah, M. N., & Mahmoud, A. M. (2019) · Antioxidants · doi:10.3390/antiox9010022 · Cited by 53
Zummo, F. P., Krishnanda, S. I., Georgiou, M., O'Harte, F. P. M., Parthsarathy, V., Cullen, K. S., Honkanen‐Scott, M., Shaw, J., Lovat, P. E., & Arden, C. (2021) · Autophagy · doi:10.1080/15548627.2021.1956123 · Cited by 43
“The finding that improving lysosomal function using targeted nanoparticles has positive effects on β-cell function in a model of nutrient excess [63], supports the targeting of lysosomal function or biogenesis to improve lipid handling in T2D.”
BackgroundInfluentialMitochondrial bioenergetics, metabolism, and beyond in pancreatic β-cells and diabetes
Nieves, A. M. R., Wauford, B. M., & Fu, A. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354199 · Cited by 57
Dayeh, T., & Ling, C. (2015) · Biochemistry and Cell Biology · doi:10.1139/bcb-2015-0057 · Cited by 45
Self-citationFunctional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Purnell, J. Q., Johnson, G., Wahed, A. S., Man, C. D., Piccinini, F., Cobelli, C., Prigeon, R. L., Goodpaster, B. H., Kelley, D. E., Staten, M. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4553-y · Cited by 43
Daneshpajooh, M., Eliasson, L., Bacos, K., & Ling, C. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1201-4 · Cited by 40
Self-citationCamargo, A., Jiménez-Lucena, R., Alcala-Diaz, J. F., Rangel-Zúñiga, O. A., García‐Carpintero, S., López-Moreno, J., Blanco-Rojo, R., Delgado‐Lista, J., Pérez‐Martínez, P., van Ommen, B., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.03.016 · Cited by 38
PRMT1 Is Required for the Maintenance of Mature β-Cell Identity
Kim, H., Yoon, B.-H., Oh, C.-M., Lee, J., Lee, K., Song, H., Kim, E., Yi, K., Kim, M., Kim, H., et al. (2019) · Diabetes · doi:10.2337/db19-0685 · Cited by 38
Glynn, E. J., Thompson, B. M., Vadrevu, S., Lu, S., Kennedy, R. T., Ha, J., Sherman, A., & Satin, L. S. (2015) · Endocrinology · doi:10.1210/en.2015-1563 · Cited by 43
John, A. N., & Jiang, F. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.12.002 · Cited by 43
Li, W., Jiao, X., Song, J., Sui, B., Guo, Z., Zhao, Y., Li, J., Shi, S., & Huang, Q. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0303 · Cited by 38
Saunders, D. C., Aamodt, K. I., Richardson, T. M., Hopkirk, A. L., Aramandla, R., Poffenberger, G., Jenkins, R., Flaherty, D. K., Prasad, N., Levy, S., et al. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00129-z · Cited by 38
Self-citationZhang, Y., Liu, P., Zhou, W., Hu, J., Cui, L., & Chen, Z. (2023) · Obesity · doi:10.1002/oby.23701 · Cited by 47
“Chronic excess insulin secretion can progress to β-cell dysfunction and finally lead to the occurrence of diabetes [73, 74].”
BackgroundLi, L.-Z., Krznar, P., Erban, A., Agazzi, A., Martin-Levilain, J., Supale, S., Kopka, J., Zamboni, N., & Maechler, P. (2019) · Diabetes · doi:10.2337/db19-0131 · Cited by 34
Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 44
Amyloid Proteins and Peripheral Neuropathy
Albariqi, M. M. H., Engelsman, S., Eijkelkamp, N., & Höppener, J. W. M. (2020) · Cells · doi:10.3390/cells9061553 · Cited by 41
Pancreatic islet beta cell-specific deletion of G6pc2 reduces fasting blood glucose
Bosma, K. J., Rahim, M., Singh, K., Goleva, S. B., Wall, M. L., Xia, J., Syring, K. E., Oeser, J. K., Poffenberger, G., McGuinness, O. P., et al. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0031 · Cited by 32
Self-citationIslet pericytes convert into profibrotic myofibroblasts in a mouse model of islet vascular fibrosis
Gonçalves, L. M., Pereira, E., Werneck‐de‐Castro, J. P., Bernal‐Mizrachi, E., & Almaça, J. (2020) · Diabetologia · doi:10.1007/s00125-020-05168-7 · Cited by 42
Ahn, M., Oh, E., McCown, E. M., Wang, X., Veluthakal, R., & Thurmond, D. C. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154431 · Cited by 37
The β-cell glucose toxicity hypothesis: Attractive but difficult to prove
Weir, G. C., Butler, P. C., & Bonner‐Weir, S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154870 · Cited by 38
Self-citationNutrient Regulation of Pancreatic Islet β-Cell Secretory Capacity and Insulin Production
Rohli, K. E., Boyer, C. K., Blom, S. E., & Stephens, S. B. (2022) · Biomolecules · doi:10.3390/biom12020335 · Cited by 41
“Early signs of t e failing β-cell include secretory dysfunction [29,30], such as impaired proinsulin processing, hyperproinsulinemia, and a decline in the pool of mature insulin-containing secretory granules [24,29,31–34].”
BackgroundInfluentialHanefeld, M., Monnier, L., Schnell, O., & Owens, D. R. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0153-3 · Cited by 37
Sheng, J., Wang, L., Tang, P. M., Wang, H., Li, J., Xu, B., Xue, V. W., Tan, R., Jin, N., Chan, T., et al. (2021) · Theranostics · doi:10.7150/thno.51857 · Cited by 34
Ultra-high resolution MALDI-FTICR-MSI analysis of intact proteins in mouse and human pancreas tissue
Piga, I., Heijs, B., Nicolardi, S., Giusti, L., Marselli, L., Marchetti, P., Mazzoni, M. R., Lucacchini, A., & McDonnell, L. A. (2017) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2017.11.001 · Cited by 32
Islet microRNAs in health and type-2 diabetes
Wendt, A., Esguerra, J. L. S., & Eliasson, L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.003 · Cited by 34
Macrophages and neutrophils are necessary for ER stress-induced β cell loss
Yang, B., Yang, L., Wang, Y., Maddison, L. A., Tang, Z., Haigh, S., Gong, Y., Zhang, Y., Covington, B. A., Bosma, K. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111255 · Cited by 33
“Whether the increase in islet macrophages is a cause or consequence of β cell death remains unresolved (Halban et al., 2014).”
Sokolowski, E. K., Kursawe, R., Selvam, V., Bhuiyan, R. M., Thibodeau, A., Zhao, C. G., Spracklen, C. N., Ucar, D., & Stitzel, M. L. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.006 · Cited by 39
Diedisheim, M., Mallone, R., Boîtard, C., & Larger, É. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3756 · Cited by 42
Felice, J. I., Schurman, L., McCarthy, A. D., Sedlinsky, C., Aguirre, J. I., & Cortizo, A. M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.011 · Cited by 34
Pujol, J., Christinat, N., Ratinaud, Y., Savoia, C., Mitchell, E. S., & Dioum, E. M. (2018) · Nutrients · doi:10.3390/nu10040473 · Cited by 35
Enteroviruses and T1D: Is It the Virus, the Genes or Both which Cause T1D
Geravandi, S., Liu, H., & Maedler, K. (2020) · Microorganisms · doi:10.3390/microorganisms8071017 · Cited by 35
Skytte, M. J., Samkani, A., Astrup, A. V., Frystyk, J., Rehfeld, J. F., Holst, J. J., Madsbad, S., Burling, K., Fenger, M., Thomsen, M. N., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00165.2020 · Cited by 48
β-Cell Succinate Dehydrogenase Deficiency Triggers Metabolic Dysfunction and Insulinopenic Diabetes
Lee, S., Xu, H., Vleck, A. V., Mawla, A. M., Li, A. M., Ye, J., Huising, M. O., & Annes, J. P. (2022) · Diabetes · doi:10.2337/db21-0834 · Cited by 35
Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function
Riopel, M., Seo, J. B., Bandyopadhyay, G. K., Li, P., Wollam, J., Chung, H., Jung, S., Murphy, A. N., Wilson, M. E., de Jong, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94330 · Cited by 32
“An impaired insulin response to glucose has long been documented in T2DM subjects (15–19), and evidence indicates that β cell dysfunction involves a decline in both β cell responsiveness to insulin secretagogues and overall β cell mass (4, 20).”
BackgroundDolenšek, J., Špelič, D., Klemen, M. S., Žalik, B., Gosak, M., Rupnik, M. S., & Stožer, A. (2015) · Sensors · doi:10.3390/s151127393 · Cited by 33
“manifests itself clinically as diabetes mellitus and studying and understanding the stimulus-secretion coupling in ever-increasing detail is crucial to understanding the pathophysiology of diabetes mellitus and to find new treatment modalities [8,9].”
BackgroundEmerging therapeutic potential for xenin and related peptides in obesity and diabetes
Craig, S. L., Gault, V. A., & Irwin, N. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3006 · Cited by 31
Prolactin Receptor Signaling Regulates a Pregnancy-Specific Transcriptional Program in Mouse Islets
Pepin, M. E., Bickerton, H. H., Bethea, M. M., Hunter, C. S., Wende, A. R., & Banerjee, R. R. (2019) · Endocrinology · doi:10.1210/en.2018-00991 · Cited by 29
Cinti, F., Mezza, T., Severi, I., Suleiman, M., CEFALO, C. M. A., Sorice, G. P., Moffa, S., Impronta, F., Quero, G., Alfieri, S., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154414 · Cited by 31
Korsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
“Type 2 diabetes (T2D) is a complex metabolic disorder involving increased insulin resistance, coupled with progressive loss of β-cell mass and function, and leading to dysregulation of insulin and glucagon secretion.(1,2) While many treatment options for T2D are available, one limitation is the risk of hypoglycaemia.”
BackgroundAdmin, A., Osipovich, A. B., Stancill, J. S., Jean-Philippe, C., D.Dudek, K., & Magnuson, M. A. (2020) · Diabetes · doi:10.2337/db19-1145 · Cited by 35
Molecular Mechanism of Pancreatic β-Cell Failure in Type 2 Diabetes Mellitus
Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Matsuoka, T., & Kaku, K. (2022) · Biomedicines · doi:10.3390/biomedicines10040818 · Cited by 29
Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes
Dalle, S., Abderrahmani, A., & Renard, É. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1076343 · Cited by 33
Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs?
Wollheim, C. B., & Maechler, P. (2015) · Nature Medicine · doi:10.1038/nm.3835 · Cited by 31
Kuo, Y., Liu, Y., & Rajesh, R. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.03.265 · Cited by 29
Obata, A., Kimura, T., Obata, Y., Shimoda, M., Kinoshita, T., Kohara, K., Okauchi, S., Hirukawa, H., Kamei, S., Nakanishi, S., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4878-1 · Cited by 28
Kang, T., Boland, B. B., Alarcón, C., Grimsby, J. S., Rhodes, C. J., & Larsen, M. R. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00160 · Cited by 27
Self-citationVertical sleeve gastrectomy triggers fast β-cell recovery upon overt diabetes
Oppenländer, L., Palit, S., Stemmer, K., Greisle, T., Sterr, M., Salinno, C., Bastidas-Ponce, A., Feuchtinger, A., Böttcher, A., Ansarullah, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101330 · Cited by 25
“Reportedly, functional loss of b -cell mass seems to be a consequence of glucolipotoxicity and oxidative, in-fl ammatory and ER stress [3].”
Lee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 33
Mouse models of peripheral metabolic disease
Xavier, G. D. S., & Hodson, D. J. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.009 · Cited by 30
Pancreatic progenitor epigenome maps prioritize type 2 diabetes risk genes with roles in development
Geusz, R. J., Wang, A., Chiou, J., Lancman, J. J., Wetton, N., Kefalopoulou, S., Wang, J., Qiu, Y., Yan, J., Aylward, A., et al. (2021) · eLife · doi:10.7554/elife.59067 · Cited by 28
Wang, X., Younis, S., Cen, J., Wang, Y., Krizhanovskii, C., Andersson, L., & Welsh, N. (2021) · Diabetologia · doi:10.1007/s00125-021-05517-0 · Cited by 26
Sulc, J., Sonrel, A., Mounier, N., Auwerx, C., Marouli, E., Darrous, L., Draganski, B., Kilpeläinen, T. O., Joshi, P. K., Loos, R. J. F., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02550-y · Cited by 33
Retnakaran, R. R., Pu, J., Emery, A., Harris, S. B., Reichert, S. M., Gerstein, H. C., McInnes, N., Kramer, C. K., & Zinman, B. (2023) · Nature Communications · doi:10.1038/s41467-023-40287-w · Cited by 25
From diabetic hyperglycemia to cerebrovascular Damage: A narrative review
Machado, R. S., Mathias, K., Joaquim, L. D. S., de Quadros, R. W., Petronilho, F. C., & Rezin, G. T. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148611 · Cited by 26
Berdan, C. A., Erion, K., Burritt, N. E., Corkey, B. E., & Deeney, J. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149008 · Cited by 28
Kurauti, M. A., Ferreira, S. M., Soares, G. M., Vettorazzi, J. F., Carneiro, E. M., Boschero, A. C., & Costa-Júnior, J. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27667 · Cited by 24
“Several factors that could lead to β‐cell dysfunction and death have been investigated including endoplasmic reticulum stress, metabolic and oxidative stress, amyloid plaque and inflammation (Halban et al., 2014).”
BackgroundEnhanced expression of β cell Ca V 3.1 channels impairs insulin release and glucose homeostasis
Yu, J. H., Shi, Y., Zhao, K., Yang, G., Yu, L., Li, Y., Andersson, E.-M., Ämmälä, C., Yang, S.-N., & Berggren, P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908691117 · Cited by 27
Giusti, L., Tesi, M., Ciregia, F., Marselli, L., Zallocco, L., Suleiman, M., Luca, C. D., Guerra, S. D., Zuccarini, M., Trerotola, M., et al. (2022) · Cells · doi:10.3390/cells11152465 · Cited by 23
“It is characterized by an absolute or relative shortage of insulin production and secretion by the pancreatic islet β-cells [1,3,4].”
BackgroundStancill, J. S., Osipovich, A. B., Cartailler, J., & Magnuson, M. A. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00229.2018 · Cited by 27
Metabolomics Analysis of Nutrient Metabolism in β-Cells
Spégel, P., & Mulder, H. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.07.020 · Cited by 26
Advances in free fatty acid profiles in gestational diabetes mellitus
Du, H., Li, D., Molive, L. M., & Wu, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04922-4 · Cited by 35
“The pathogenesis of GDM is similar to that of type 2 diabetes mellitus, which is characterized by increased insulin resistance and a decrease in β-cell function and number caused by relative insulin deficiency [5, 6].”
BackgroundShanak, S., Bassalat, N., Barghash, A., Kadan, S., Ardah, M., & Zaid, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2832889 · Cited by 23
“-e WHO characterizes hyperglycemia that is identified during pregnancy for the first time as gestational diabetes mellitus (GDM).”
BackgroundInfluentialMiura, M., Miyatsuka, T., Katahira, T., Sasaki, S., Suzuki, L., Himuro, M., Nishida, Y., Fujitani, Y., Matsuoka, T., & Watada, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.035 · Cited by 23
“As diabetes mellitus results from the absolute or relative deficiency of insulin secretion from pancreatic β cells [8], the generation of surrogate β cells has been a target for the cure of diabetes.”
BackgroundJiang, H., Tong, Y.-X., Yan, D., Jia, S., Östenson, C., & Chen, Z. (2015) · Scientific Reports · doi:10.1038/srep15599 · Cited by 25
Liu, L., Liu, J., Xu, L., Ke, W., Wan, X., Li, H., He, X., Wang, L., Cao, X., Xiao, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12782 · Cited by 28
The eye as a novel imaging site in diabetes research
Yang, S.-N., & Berggren, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.005 · Cited by 24
Preserved Proinsulin Secretion in Long-Standing Type 1 Diabetes
Steenkamp, D., Cacicedo, J. M., Sahin-Efe, A., Sullivan, C. A. W., & Sternthal, E. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0009 · Cited by 22
Lima‐Cabello, E., Morales, S., Foley, R. C., Melser, S., Alché, V., Siddique, K. H. M., Singh, K. B., Ramírez, J. D. D. A., & Jiménez-López, J. C. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.11.040 · Cited by 30
Li, Y., Li, Y., Chen, N., Feng, L., Gao, J., Zeng, N., He, Z., & Gong, Q. (2022) · Antioxidants · doi:10.3390/antiox11091705 · Cited by 26
Retnakaran, R., Choi, H., Ye, C., Kramer, C. K., & Zinman, B. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13236 · Cited by 21
Epigenetics in β-cell adaptation and type 2 diabetes
Kim, H., & Kulkarni, R. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.008 · Cited by 26
“Type 2 diabetes (T2D) is a chronic disease that is characterized by insulin resistance and hyperglycemia [1].”
BackgroundRetnakaran, R. R., Emery, A., Ye, C., Harris, S. B., Reichert, S. M., McInnes, N., Gerstein, H. C., Thorpe, K. E., Kramer, C. K., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14421 · Cited by 22
Exosomes as biomarkers and therapy in type 2 diabetes mellitus and associated complications
Satyadev, N., Rivera, M. I., Nikolov, N. K., & Fakoya, A. O. J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1241096 · Cited by 22
Co-localization of acinar markers and insulin in pancreatic cells of subjects with type 2 diabetes
Masini, M., Marselli, L., Himpe, E., Martino, L., Bugliani, M., Suleiman, M., Boggi, U., Filipponi, F., Occhipinti, M., Bouwens, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179398 · Cited by 21
Aminoguanidine reduces diabetes‑associated cardiac fibrosis
Magdaleno, F., Blajszczak, C. C., Niño, C. L. C., Guadrón‐Llanos, A. M., V�zquez‐�lvarez, A., Miranda‐D�az, A., Nieto, N., Islas‐Carbajal, M., & Rincón‐Sánchez, A. R. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7921 · Cited by 22
Lang, A., Kuß, O., Filla, T., & Schlesinger, S. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02401-2 · Cited by 25
Rasouli, N., Younes, N., Utzschneider, K. M., Inzucchi, S. E., Balasubramanyam, A., Cherrington, A., Ismail‐Beigi, F., Cohen, R. M., Olson, D. E., DeFronzo, R. A., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1787 · Cited by 22
Self-citationImplications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases
Mosa, R., Zhang, Z., Shao, R., Deng, C., Chen, J., & Chen, C. (2015) · Endocrine · doi:10.1007/s12020-015-0531-z · Cited by 20
Metadata
- Authors
- Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C.
- Affiliations
- University of Geneva (CH)
- University of Chicago (US)
- Wake Forest University (US)
- Albert Einstein College of Medicine (US)
- Lund University (SE)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Columbia University (US)
- Joslin Diabetes Center (US)
- Corresponding author
- Halban, Philippe A.
- Polonsky, Kenneth S.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1751-1758
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4179518
- OpenAlex
- W2142418958
- Semantic Scholar
- b30b808a69da53c538eed4ffb6c8ae812e4bfe16
- Cited by
- 460
- References
- 91
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 30 · 2023: 38 · 2022: 41 · 2021: 37 · 2020: 49 · 2019: 50 · 2018: 46 · 2017: 57 · 2016: 29 · 2015: 30 · 2014: 3
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- University of Pennsylvania
- University of Washington
- University of Exeter
- Vrije Universiteit Amsterdam
- Lunds Universitet
- Novo Nordisk
- Università di Pisa
- Novo Nordisk Fonden (NNF11OC1014546)
- National Institutes of Health (UL1TR000430)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082590, P30DK020593, P30DK020595)
- National Center for Advancing Translational Sciences
- Children's Hospital of Pittsburgh
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- beta-cell failure, type 2 diabetes, beta-cell dysfunction, beta-cell mass, genetic susceptibility, diabetes prevention, diabetes treatment, genetic loci, cell therapy, bariatric surgery, circulating factors
- MeSH terms
- Congresses as Topic, Diabetes Mellitus, Type 2, Expert Testimony, Humans, Signal Transduction, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.